1-(2,2,2-三氟乙基)-4-哌啶胺 | 187217-99-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(2,2,2-三氟乙基)-4-哌啶胺
• 中文别名: 1-(2,2,2-三氟乙基)哌啶-4-胺
• 英文名称: 1-(2,2,2-trifluoroethyl)piperidin-4-amine
• 英文别名: 1-(2,2,2-trifluoroethyl)piperidin-4-ylamine
• CAS: 187217-99-8
• 化学式: C₇H₁₃F₃N₂
• mdl: MFCD09040660
• 分子量: 182.189
• InChiKey: JJGAYYBQGNJNJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  161.8±40.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-(2,2,2-三氟乙基)-4-哌啶胺 在 盐酸 、 palladium on activated charcoal 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 、 异丙醇 为溶剂， 生成
  参考文献：
  名称：

  Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2

  摘要：

  Herein we describe our successful efforts in obtaining C-2 substituted imidazo-pyrrolopyridines with improved JAK1 selectivity relative to JAK2 by targeting an amino acid residue that differs between the two isoforms (JAK1: E966; JAK2: D939). Efforts to improve cellular potency by reducing the polarity of the inhibitors are also detailed. The X-ray crystal structure of a representative inhibitor in complex with the JAK1 enzyme is also disclosed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.008
• 作为产物：
  描述：

  2,2,2-trifluoro-1-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)ethan-1-one 在 盐酸 、 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 20.0 ℃ 、275.8 kPa 条件下， 反应 78.0h， 生成 1-(2,2,2-三氟乙基)-4-哌啶胺
  参考文献：
  名称：

  Lead Optimization toward Proof-of-Concept Tools for Huntington’s Disease within a 4-(1H-Pyrazol-4-yl)pyrimidine Class of Pan-JNK Inhibitors

  摘要：

  Through medicinal chemistry lead optimization studies focused on calculated properties and guided by X-ray crystallography and computational modeling, potent pan-JNK inhibitors were identified that showed submicromolar activity in a cellular assay. Using in vitro ADME profiling data, 9t was identified as possessing favorable permeability and a low potential for efflux, but it was rapidly cleared in liver microsomal incubations. In a mouse pharmacokinetics study, compound 9t was brain-penetrant after oral dosing, but exposure was limited by high plasma clearance. Brain exposure at a level expected to support modulation of a pharmacodynamic marker in mouse was achieved when the compound was coadministered with the pan-cytochrome P450 inhibitor 1-aminobenzotriazole.

  DOI：

  10.1021/jm5013598

文献信息

• [EN] 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'AZÉTIDINE OU DE CYCLOBUTANE 1,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROSTAGLANDINE D SYNTHASE HÉMATOPOÏÉTIQUE (H-PGDS)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018069863A1

  公开（公告）日：2018-04-19

  A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式（I）的化合物，其中R、R1、R2、R3、Y、Y1、a、X和Z的定义如本文所述。本发明的化合物是造血前列腺素D合成酶（H-PGDS）的抑制剂，可用于治疗杜兴氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗相关疾病的方法。
• On-Chip Screening of a Glycomimetic Library with C-Type Lectins Reveals Structural Features Responsible for Preferential Binding of Dectin-2 over DC-SIGN/R and Langerin
  作者：Laura Medve、Silvia Achilli、Sonia Serna、Fabio Zuccotto、Norbert Varga、Michel Thépaut、Monica Civera、Corinne Vivès、Franck Fieschi、Niels Reichardt、Anna Bernardi

  DOI：10.1002/chem.201802577

  日期：2018.9.25

  A library of mannose‐ and fucose‐based glycomimetics was synthesized and screened in a microarray format against a set of C‐type lectin receptors (CLRs) that included DC‐SIGN, DC‐SIGNR, langerin, and dectin‐2. Glycomimetic ligands able to interact with dectin‐2 were identified for the first time. Comparative analysis of binding profiles allowed their selectivity against other CLRs to be probed.

  合成了一个基于甘露糖和岩藻糖的糖模拟物库，并以微阵列格式针对一组包括DC-SIGN，DC-SIGNR，Langerin和dectin-2的C型凝集素受体（CLR）进行了筛选。首次鉴定出能够与dectin-2相互作用的拟模拟配体。结合概况的比较分析允许探测其对其他CLR的选择性。
• HALO-SUBSTITUTED PYRIMIDODIAZEPINES
  申请人：Cai Jianping

  公开号：US20090318408A1

  公开（公告）日：2009-12-24

  The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.

  本发明提供了公式I的PLK1抑制剂化合物： 用于治疗或控制细胞增殖性疾病，特别是肿瘤性疾病。这些化合物和含有这些化合物的配方可能在治疗或控制实体肿瘤方面有用，例如乳腺癌、结肠癌、肺癌和前列腺癌等固体肿瘤，以及非霍奇金淋巴瘤等其他肿瘤性疾病。还提供了在合成公式I化合物中有用的中间体化合物。
• Heteroalkylamino-substituted bicyclic nitrogen heterocycles
  申请人：Syntex (U.S.A.) LLC

  公开号：US06451804B1

  公开（公告）日：2002-09-17

  The invention provides compounds represented by the formula: wherein R1, R2, R3, R4, and n are as defined in the Summary of the Invention; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

  本发明提供了由以下公式表示的化合物：其中R1、R2、R3、R4和n如发明总结中定义；以及单个异构体、外消旋或非外消旋异构体混合物，以及药用可接受的盐。本发明进一步涉及包含这些化合物的药物组合物、它们作为治疗剂的使用方法以及它们的制备方法。
• [EN] SULFONYLUREA DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE SULFONYLURÉE ET LEURS UTILISATIONS
  申请人：NODTHERA LTD

  公开号：WO2020249664A1

  公开（公告）日：2020-12-17

  The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

  本公开涉及式(I)化合物及其前药、药用可接受盐、药物组合物、使用方法和制备方法。所公开的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟，并可用于治疗炎症、自身炎症和自身免疫疾病以及癌症等炎症小体活性涉及的疾病。